Brian Baranick - EXACT Sciences Executive Oncology
| EXAS Stock | USD 52.91 0.16 0.30% |
Executive
Brian Baranick is Executive Oncology of EXACT Sciences
| Age | 46 |
| Address | 5505 Endeavor Lane, Madison, WI, United States, 53719 |
| Phone | 608 284 5700 |
| Web | https://www.exactsciences.com |
Latest Insider Transactions
Brian Baranick Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Baranick against EXACT Sciences stock is an integral part of due diligence when investing in EXACT Sciences. Brian Baranick insider activity provides valuable insight into whether EXACT Sciences is net buyers or sellers over its current business cycle. Note, EXACT Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell EXACT Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Baranick over two months ago Disposition of 929 shares by Brian Baranick of EXACT Sciences at 70.0 subject to Rule 16b-3 |
EXACT Sciences Management Efficiency
The company has return on total asset (ROA) of (0.0216) % which means that it has lost $0.0216 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0676) %, meaning that it created substantial loss on money invested by shareholders. EXACT Sciences' management efficiency ratios could be used to measure how well EXACT Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.1 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, EXACT Sciences' Intangibles To Total Assets are comparatively stable compared to the past year. Debt To Assets is likely to gain to 0.38 in 2024, whereas Fixed Asset Turnover is likely to drop 1.58 in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matthew Henn | Seres Therapeutics | 49 | |
| RPh Young | Seres Therapeutics | 57 | |
| David Ege | Seres Therapeutics | 49 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Nicole Esq | HCW Biologics | N/A | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Alpa Parikh | Lumos Pharma | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Lee Flowers | HCW Biologics | 78 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| MD FAAP | Lumos Pharma | N/A | |
Management Performance
| Return On Equity | -0.0676 | ||||
| Return On Asset | -0.0216 |
EXACT Sciences Leadership Team
Elected by the shareholders, the EXACT Sciences' board of directors comprises two types of representatives: EXACT Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EXACT. The board's role is to monitor EXACT Sciences' management team and ensure that shareholders' interests are well served. EXACT Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EXACT Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey CFA, Chief Officer | ||
| Kevin Conroy, Chairman of The Board, CEO and Pres | ||
| Ana Hooker, Chief Officer | ||
| Aaron Bloomer, Executive Finance | ||
| James Herriott, General VP | ||
| Vic Parker, Head Sales | ||
| Sarah Condella, Executive Resources | ||
| Sri Kalluri, Chief Officer | ||
| Tim Caprez, Chief VP | ||
| Brian Baranick, Executive Oncology | ||
| Nassar Nizami, Chief Officer | ||
| Everett Cunningham, Chief Officer | ||
| Scott Coward, Sr. VP and General Counsel | ||
| Jake MBA, Executive Screening | ||
| Graham Lidgard, Chief Science Officer and Sr. VP | ||
| Kevin JD, Chairman CEO | ||
| Jorge Garces, Chief Officer | ||
| Megan Jones, Associate Relations |
EXACT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EXACT Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0676 | ||||
| Return On Asset | -0.0216 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | (0.03) % | ||||
| Current Valuation | 11.53 B | ||||
| Shares Outstanding | 185.08 M | ||||
| Shares Owned By Insiders | 1.01 % | ||||
| Shares Owned By Institutions | 98.99 % | ||||
| Number Of Shares Shorted | 14.06 M | ||||
| Price To Earning | (38.17) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for EXACT Stock Analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.